Search results
Results from the WOW.Com Content Network
The 'German Network for Bioinformatics Infrastructure – de.NBI' is a national, academic and non-profit infrastructure initiated by the Federal Ministry of Education and Research funding 2015-2021. The network provides bioinformatics services to users in life sciences research and biomedicine in Germany and Europe.
BioNTech was founded in 2008 based on research by Uğur Şahin, Özlem Türeci, [8] and Christoph Huber, [9] with a seed investment of €180 million [10] from MIG Capital, a Munich-based venture capital firm, the family office of Andreas and Thomas Strüngmann, and the present chairman of the supervisory board, Helmut Jeggle.
CureVac is a leading German biotech in the race to develop a COVID-19 vaccine
The International Max Planck Research School for Molecules of Life (short: IMPRS-ML) is a German centre for postgraduate training and research in life sciences. It is one among over 60 International Max Planck Research Schools in Germany. It is located in Munich and was established in 2005.
The federal state of Rhineland-Palatinate financed the construction of a new building, starting in December 2009 on the campus of the University of Mainz. In May 2010 developmental biologist Christof Niehrs (formerly at the German Cancer Research Center, DKFZ) was appointed as the institute's founding director. The institute was then named ...
The centre focuses on investigating infectious diseases caused by bacteria and viruses. Further research topics are the immune system and the development of novel anti-infective drugs. The HZI was founded on 18 July 2006 by renaming the Gesellschaft für Biotechnologische Forschung mbh (GBF, German Research Centre for Biotechnology). [3]
The Max Planck Institute for Biology Tübingen is a research institute located in Tübingen, Germany, and was formerly known as the Max Planck Institute for Developmental Biology. A predecessor institution operated under the same name from 1948 to 2004. Max Planck Institute for Biology in Tübingen, Germany
The new site will add cleanroom space of approximately 2,050 m 2 (22,066 ft 2), and the highly automated facility will feature four new 2,000-liter (528 gal) single-use bioreactors. The focus of the new facility will be on the commercial production of complex molecules for clients in the US. [16] [17]